[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-loss":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,43,75,102,128,155,182,206,232,253,277,309,327,344,368,393,410,436,467,491,514,568,588,609,630],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100644130","influence-of-acetal-resin-versus-nylon-elastic-cap-on-crestal-bone-loss-in-mandibular-implant-supported-overdenture-100644130",false,"NCT07666763","Influence of Acetal Resin Versus Nylon Elastic Cap on Crestal Bone Loss in Mandibular Implant-Supported Overdenture","AcetalResin","Inclusion Criteria:\n\n* Completely edentulous mandible.\n* Sufficient bone height\u002Fwidth in mandibular residual ridges.\n* Angles classification class I.\n* Sufficient inter-arch distance\n\nExclusion Criteria:\n\n* TMJ disorders.\n* Diabetic\n* Hypertensive\n* Cancer patients.\n* Smoker\n* Osteoporosis.\n* Immunosuppressive disease\n* Any disease affecting bone\u002Fimplant stability.",true,"MALE","40 Years","60 Years",{"count":22,"type":23},22,"ESTIMATED","INTERVENTIONAL",[26],"NA","Objective: To evaluate and compare the effect of two different attachment housing materials-Acetal Resin (Polyoxymethylene) versus conventional Nylon elastic caps-on marginal crestal bone loss around dental implants supporting a mandibular overdenture. It also evaluates peri-implant clinical tissue health by measuring pocket depth and the gingival bleeding index.",[29,30],"Bone Loss","Pocket, Periodontal","NOT_YET_RECRUITING","2026-06-21",{"date":34,"type":35},"2026-06-24","ACTUAL",{"date":37,"type":23},"2026-07-01",{"date":39,"type":23},"2027-08-01",{"name":41,"class":42},"Future University in Egypt","OTHER",{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":51,"minAge":20,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100498013","phase-4-bone-exercise-alendronate-and-caloric-restriction-100498013","NCT05764733","Bone, Exercise, Alendronate, and Caloric Restriction","The Bone, Exercise, Alendronate, and Caloric Restriction Trial","BEACON","Inclusion Criteria:\n\n* Community-dwelling\n* BMI\\>30 kg\u002Fm\\^2 or BMI 25.0 to \\\u003C30 kg\u002Fm\\^2 plus one risk factor\n* Currently receiving routine (annual) dental care\n* Pre-existing low bone mass (T-score ≤-1.1 to \\>-2.5 at the hip, femoral neck, or lumbar spine (L1-L4))\n\nExclusion Criteria:\n\n* Weight greater than 450 lbs (DXA limit)\n* Resides with someone who is currently participating in BEACON\n* Dependent on quad cane or walker; inability to walk independently\n* History of mild cognitive impairment or dementia or evidence of cognitive impairment ((score \\\u003C20) on Montreal Cognitive Assessment (MoCA))\n* Excessive alcohol use (\\>21 drinks\u002Fweek) in the past month; any non-cannabis illicit drug use\n* Weight change ≥5% in past 3 months\n* Regular participation (\\>60 mins per day on \\> 3 days\u002Fweek) in structured strength training program for \\>6 months\n* Severe arthritis, fracture, chronic injury, or other musculoskeletal disorder that prevents safe exercise participation; joint replacement or other orthopedic surgery in past 6 months or planned in next 12 months; invasive dental procedure (i.e. extraction\u002Fimplant) in past 6 month or planned in next 12 months\n* Osteoporosis (any of the following): Self-reported and on prescription osteoporosis medication; self-reported prior spine, hip, wrist, or shoulder fracture after age 40 (except when caused by trauma or fall from height), including atypical femoral fractures (AFF); or ≥20% for major osteoporotic fracture at screening\n* Uncontrolled hypertension (systolic \\>180 OR diastolic \\>110 mmHg) upon repeated assessments (up to 3 times)\n* Uncontrolled type 2 diabetes (HbA1c \\>8%); dialysis or abnormal kidney function (eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m2); liver disease or abnormal liver function (ALT levels 2 times above normal); anemia (Hb\\\u003CLLN); calcium above or below normal limit; uncontrolled thyroid disease (hypo\u002Fhyper) or requiring recent (past 3 months) adjustments in thyroid hormone supplementation or thyroid-stimulating hormone \\\u003CLLN or \\>10 mIU\u002Fml; vitamin D deficiency (\\\u003C20 ng\u002FmL).\n* Stroke, heart attack, heart failure hospitalization, or revascularization procedure within the past 6 months; chronic respiratory disease requiring oxygen; PAD diagnosis within the last 12 months; uncontrolled angina; progressive neurological disease; malabsorption disorder; any disease suggesting a life-expectancy \\\u003C3 years; bilateral hip replacement; past or planned bariatric surgery; cancer requiring initial treatment within the last 12 months (except non-melanoma skin cancers); major vision or hearing loss; unstable gastric reflux; esophageal stricture, achalasia, or Barrett's esophagus\n* Daily use of growth hormones, weight loss medications, oral steroids, or diabetes prescriptions (such as insulin, thiazolidinediones, or canagliflozin); known allergy to bisphosphonates; prior use of oral bisphosphonates for \\>3 months within the past 3 years; zoledronic acid within the past 5 years; denosumab use within the past year; anabolic agents for \\>3 months in the last year; current use of biotin or strontium; history of 3+ years of antiresorptive therapy\n* Unable\u002Funwilling to: provide own transportation to study visits, commit to study protocol (including random assignment), or adhere to data collection visits\n* Current participation in another intervention research study; planned out-of-town trip greater than 1 month at a time during the first 6 months of the study; unwilling to provide informed consent, including consent to access personal electronic health records; judged unsuitable for the trial for any reason by research team","ALL",{"count":53,"type":23},900,[55],"PHASE4","The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight. Participation in this research will involve up to nine assessment visits and last up to two years.",[29],[59,60,61,62,63],"Older Adults","Weight Loss","Resistance Training","Osteoporosis","Osteopenia","RECRUITING","2026-06-08",{"date":67,"type":35},"2026-06-09",{"date":69,"type":35},"2023-06-08",{"date":71,"type":23},"2028-01",{"name":73,"class":42},"Wake Forest University Health Sciences",2,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":24,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100634474","evaluation-of-the-safety-feasibility-and-early-clinical-outcomes-of-patient-specific-bone-defect-implants-fabricated-from-titanium-alloy-ti-6al-4v-using-3d-printing-technology-100634474","NCT07540156","Evaluation of the Safety, Feasibility, and Early Clinical Outcomes of Patient-Specific Bone Defect Implants Fabricated From Titanium Alloy (Ti-6Al-4V) Using 3D Printing Technology","Inclusion Criteria:\n\n* Diagnosed with a bone defect requiring surgical reconstruction, as determined by the treating orthopedic surgeon\n* Suitable candidate for implantation of a patient-specific device manufactured from Ti-6Al-4V\n* Able to undergo preoperative imaging (CT ± MRI) required for implant design\n* Willing and able to provide written informed consent\n* Willing to comply with scheduled follow-up visits and study assessments\n\nExclusion Criteria:\n\n* Active systemic or local infection at the surgical site at the time of implantation\n* Known hypersensitivity or allergy to titanium or titanium alloys\n* Severe uncontrolled comorbidities that significantly increase surgical risk (e.g., uncontrolled diabetes, severe cardiovascular disease)\n* Pregnant or breastfeeding women\n* Participation in another interventional clinical study that may interfere with the outcomes of this study\n* Inability to complete follow-up assessments within the required timeframe",{"count":82,"type":23},10,[26],"The goal of this clinical trial is to evaluate the safety and feasibility of patient-specific bone defect implants fabricated from Ti-6Al-4V using 3D printing technology and to assess early clinical outcomes within the first 12 months following implantation of these customized devices. The main question it aims to answer is: \"In patients with bone defects requiring surgical reconstruction, are patient-specific bone defect implants fabricated from titanium alloy (Ti-6Al-4V) using 3D printing technology - designed and produced at VinUni, safe and feasible for clinical use, and do they result in favorable early clinical outcomes within the first 12 months following implantation?\"",[29,86],"Bone Defects",[88,89,90,91],"Bone defect reconstruction","Patient-specific implants","Three-dimensional (3D) printing","Titanium alloy Ti-6Al-4V","2026-04-16",{"date":94,"type":35},"2026-04-20",{"date":96,"type":23},"2026-04-01",{"date":98,"type":23},"2028-12-31",{"name":100,"class":42},"VinUniversity",1,{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":17,"sex":51,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":101},"100414005","release-kinetics-of-rhbmp-2-using-e-prf-as-an-autologous-carrier-an-in-vitro-analysis-100414005","NCT04670965","Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis","Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An in Vitro Analysis","Inclusion Criteria:\n\n* English speaking\n* At least 18 years old\n* Must be a patient of the UAB Dental School\n* Able to read and understand informed consent document\n* Previously treatment planned for a periodontal procedure that will utilize PRF, i.e. requiring venipuncture, as a part of the routine clinical care.\n\nExclusion Criteria:\n\n* Non-English speaking\n* Less than 18 years old\n* Smokers\u002Ftobacco users (\\>10 cigarettes\u002Fday)\n* Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing as assessed by Board Certified Periodontal faculty at UAB Department of Periodontology\n* Patient-reported serious adverse events reported with venipuncture, blood sample collection, and\u002For blood donation.","18 Years","99 Years",{"count":112,"type":23},20,"OBSERVATIONAL","This study is seeking to evaluate the binding of a commercially-available, recombinant human osteoinductive growth factor, rhBMP-2, to a human blood derived product scaffold, enhanced Platelet-rich fibrin (E-PRF), and the release of such a growth factor over time in an in vitro (laboratory) environment. The investigators will compare these release kinetics to those of the FDA approved carrier for rhBMP-2, an absorbable collagen sponge (ACS), a combination of E-PRF and ACS, and E-PRF alone.",[29],[117,118,119,120],"Platelet concentrates","Platelet-rich fibrin","Growth factor","Bone morphogenic protein",{"date":94,"type":35},{"date":123,"type":23},"2026-09",{"date":125,"type":23},"2028-07",{"name":127,"class":42},"University of Alabama at Birmingham",{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":51,"minAge":109,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":24,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":101},"100557702","comparison-of-bone-microarchitecture-analysed-by-hrpqct-and-pqct-in-pathologies-with-bone-loss-andor-muscle-loss-100557702","NCT06541548","Comparison of Bone Microarchitecture Analysed by HRpQCT and pQCT in Pathologies With Bone Loss and\u002For Muscle Loss","Comparison of Bone Microarchitecture Analysed by High Resolution Peripheral Microscanner (HR-pQCT) and Peripheral Microscanner (pQCT) in Pathologies With Bone Loss and\u002For Muscle Loss","MICROS","Inclusion Criteria:\n\nFor the patients:\n\nWomen or men treated at the Saint-Etienne University Hospital and presenting an osteoporotic risk with one of the following associated pathologies:\n\n* Osteoporosis defined by: History of a documented brittle bone fracture\n* Bone fragility: Patient with indication for bone densitometry but no history of fracture\n* Inflammatory joint disease:\n\n  * Rheumatoid arthritis\n  * Spondyloarthritis\n* Chronic kidney disease\n* Endocrinopathies:\n\n  * Primary hyperparathyroidism\n  * Constitutional thinness\n  * Anorexia nervosa\n  * Obesity (BMI \\>30)\n  * Sarcopenia\n* Neuropathies - Parkinson's disease\n\nFor the controls:\n\nAcute episode of spinal or radiculalgia (less than one month old) with corticosteroid treatment of less than 1 month Signature of written consent\n\nExclusion Criteria:\n\n* No sign written consent\n\nFor the controls:\n\n* Medications inducing bone loss:\n* anti-aromasin or GnRH agonist for at least 6 months,\n* corticosteroids (dose ≥ 5 mg\u002Fd for 6 months)\n* anti-epileptic drugs: carbamazepine, phenobarbital, phenytoin, primidone, valproic acid for at least 6 months)\n* History of fracture due to bone fragility\n* Taking bone-targeting medication (biphosphonate, teriparatide, strontium ranelate)",{"count":137,"type":23},1000,[26],"The study aims to utilize medical devices, such as the Xtreme CT and XCT 3000, to assess bone and muscle microarchitecture for various pathologies. The devices provide crucial data on bone and muscle density, aiding in understanding fracture risks associated with conditions like rheumatoid arthritis and neurological disorders. Current methods like DXA scanning have limitations in predicting fracture risks accurately due to their inability to assess cortical and trabecular microstructure. The study emphasizes the importance of evaluating cortical porosity and trabecular volume loss, especially in conditions like post-menopausal osteoporosis and sarcopenia. Additionally, it explores the impact of neurological disorders, renal insufficiency, and endocrinopathies on bone health. Furthermore, the study aims to establish a control group to differentiate pathological changes from age-related variations. Expected outcomes include a comprehensive understanding of bone microarchitecture alterations across various pathologies and the potential to improve fracture risk estimation beyond conventional methods like DEXA scanning. Ultimately, the study anticipates facilitating better management strategies to reduce fracture risks associated with these conditions.",[141,29],"Osteoporosis Risk",[143,144,145],"Bone microarchitecture","Bone fragility","osteoporosis","2026-02-27",{"date":148,"type":35},"2026-03-03",{"date":150,"type":35},"2026-02-02",{"date":152,"type":23},"2035-05",{"name":154,"class":42},"Centre Hospitalier Universitaire de Saint Etienne",{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":51,"minAge":109,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":101},"100556635","innovative-technologies-for-salvage-procedures-of-failed-treatments-of-osteoarthritis-biomimetics-solutions-custompn-100556635","NCT06527664","Innovative Technologies for Salvage Procedures of Failed Treatments of Osteoarthritis: Biomimetics Solutions (CustomPN)","Innovative Technologies for Cost-Effective Healthcare Delivery for Salvage Procedures of Failed Treatments of Osteoarthritis: Specific Biomimetics Solutions to Reduce a Growing Problem With a High Social and Economic Impact.(CustomPN)","CustomPN","Inclusion Criteria:\n\n* need of custom-made acetabular implant on the basis of CT and X-ray evaluation ()\n* pre-operative CT scan\n* adults patients (minimum age: 18 years)\n* complete medical charts\n* patients' availability\n\nExclusion Criteria:\n\n* oncological reasons for revision\n* other types of revision implant (non custom)\n* inadequate medical chart\n* lack of pre-operative CT scan",{"count":164,"type":23},15,"In this prospective multicenter study, a population of adult individuals consecutively treated for revision hips, requiring a custom-made acetabular implant for non-oncological reasons, will be included. The custom-made implant is a personalized implant produced using additive manufacturing, based on the pre-operative CT scan that details the bone damage. Patients eligible for this implant are those with severe acetabular bone damage Paprosky 3 (loss of the superolateral part and one of the two ventro-caudal walls).\n\nPreoperatively, the patient will undergo a clinical evaluation. Data will be collected on the patient's general health status with the Charlson score, the reason for revision, number of revisions, type of implant in place, and the time elapsed between the failed implant and the revision in question. The bone deficit will be studied through CT measurements according to qualitative and quantitative scales. During the surgery, information on intraoperative complications will be collected. In the postoperative period, perioperative complications will be collected according to the Clavien Dindo classification. The clinical radiographic evaluations will be carried out during outpatient follow-up visits at 1, 3, 12, 24, and 36 months after revision. They include the Harris Hip Score clinical score, the EQ-5D PROM, and the patient's satisfaction level (qualitative assessment in 4 grades: unsatisfied, slightly satisfied, moderately satisfied, fully satisfied). The positional parameters of the implant will be evaluated, as compared to the immediate post-operative X-ray: acetabular abduction, acetabular anteversion, center of rotation height, center of rotation medialization, and inclination of the custom-made component. From 12 months onwards, the osteointegration characteristics of the component will be assessed: presence of radial trabeculae at the interface, superolateral and inferior reinforcements, stress shielding, absence of radiolucent lines. Re-revision rates will be determined using the Kaplan-Meier method. The reasons for re-revision will be noted.",[29,167,168],"Hip Prosthesis Infection","Arthroplasty Complications",[170,171,172],"revision hip arthroplasty","custom-made implant","additive manufacturing","2026-02-19",{"date":175,"type":35},"2026-02-23",{"date":177,"type":35},"2024-10-01",{"date":179,"type":23},"2026-09-30",{"name":181,"class":42},"Istituto Ortopedico Rizzoli",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":51,"minAge":188,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":24,"phases":191,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":101},"100433300","phase-3-bisphosphonate-use-to-mitigate-bone-loss-secondary-to-bariatric-surgery-100433300","NCT04922333","Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery","Inclusion Criteria:\n\n* Subjects who have had sleeve gastrectomy\n* Willing to provide informed consent\n* Agree to all study procedures and assessments.\n\nExclusion Criteria:\n\n* Weight greater than 450 lbs\n* Regular use of growth hormones, oral steroids, or prescription osteoporosis medications;\n* Known allergies to bisphosphonates\n* Unstable gastric reflux requiring two or more additional doses per month of anti-reflux medication.\n* Current participation in other research study\n* Unable to provide own transportation to study visits\n* Unable to position on scanner independently.","30 Years",{"count":190,"type":23},200,[192],"PHASE3","The purpose of this research study is to see whether receiving a bisphosphonate medication called risedronate can reduce bone and muscle loss following bariatric surgery. Participation will involve up to 6 study visits and last about 1 year. Risedronate is a medication that prevents bone breakdown and has been approved by the US Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in older men and women. However, risedronate has not been approved for the prevention of bone and muscle loss following vertical sleeve gastrectomy.\n\nParticipation in this study will involve completing two visits before beginning the intervention. Participants who qualify will be scheduled to begin the intervention program which will involve taking 6 monthly doses of a risedronate or placebo pill. Participants will then receive monthly contacts by study staff during this time to remind participants to take the intervention pill and ask about any adverse events. After the completion of intervention period, participants will complete up to 4 follow up study visits at 6 months (2 visits) and at 12 months (2 visits).",[29],[196,197,198],"bariatric surgery","bisphosphonate","mitigate bone loss","2026-02-17",{"date":173,"type":35},{"date":202,"type":35},"2023-03-28",{"date":204,"type":23},"2028-04-30",{"name":73,"class":42},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":51,"minAge":109,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":24,"phases":214,"briefSummary":215,"conditions":216,"keywords":220,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":101},"100457513","minimally-invasive-sinus-lift-through-the-interradicular-septum-100457513","NCT05237570","Minimally Invasive Sinus Lift Through the Interradicular Septum","Minimally Invasive Microsurgical Sinus-lift Through the Interradicular Septum. A Clinical Trial","Inclusion Criteria:\n\n* Patient older than 18 years.\n* Plaque index and bleeding index less than 30%.\n* Invagination of the sinus cavity in the interradicular area of the upper first molar.\n* Upper first molar not restorable and with height of the interradicular remnant less than 5 mm.\n\nExclusion Criteria:\n\n* Presence of systemic disease contraindicating the intervention.\n* Pregnant women.",{"count":112,"type":23},[26],"This study aims to describe a new approach for the reconstruction of the alveolar process in the sinus area. This minimally invasive approach will access the maxillary sinus through the alveolar process, elevating the sinus membrane in the area immediately above it. The regeneration may be achieved in the specific area required for dental implant placement, reducing the morbidity of the procedure.",[29,217,218,219],"Bone Loss, Age-related","Atrophy; Alveolar Process","Surgical Procedure, Unspecified",[221,222,223],"maxillary sinus","sinus lift","xenograft","2026-02-16",{"date":199,"type":35},{"date":227,"type":35},"2021-03-02",{"date":229,"type":23},"2027-02-01",{"name":231,"class":42},"Universidad de Murcia",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":101},"100620130","all-on-x-stackable-guides-for-maxillary-terminal-dentition-100620130","NCT07353619","All-on-X Stackable Guides for Maxillary Terminal Dentition","All-on-X (Full-arch Implant-supported Rehabilitation) Stackable Surgical Guides for Maxillary Terminal Dentition: a 2-year Retrospective Analysis","Inclusion Criteria:\n\nAdult patients presenting with terminal dentition of the maxillary arch\n\nRehabilitation with a maxillary All-on-6 implant-supported complete fixed dental prosthesis\n\nTreatment performed using a fully digital stackable guided surgery workflow\n\nImmediate loading with a provisional fixed prosthesis\n\nAvailability of complete clinical and radiographic records\n\nMinimum follow-up period of 2 years\n\nProsthetic design classified as (Fixed prosthesis) FP-1 or FP-2 according to Misch classification\n\nExclusion Criteria:\n\nUncontrolled systemic conditions contraindicating implant surgery\n\nHistory of head and neck radiotherapy\n\nPresence of untreated periodontal or peri-implant infection at the time of surgery\n\nIncomplete or missing clinical or radiographic records\n\nCases requiring simultaneous bone grafting procedures\n\nSevere maxillary atrophy (Cawood and Howell Class III-V)\n\nCases requiring FP-3 prosthetic design\n\nRehabilitation performed without guided surgery or without immediate loading","70 Years",{"count":241,"type":23},40,"This retrospective study will evaluate the clinical performance of maxillary All-on-X(full-arch implant-supported rehabilitation) implant rehabilitation using stackable guided surgery and immediate loading. Implant survival and peri-implant outcomes will be assessed over a 2-year follow-up, with regression analysis will be used to investigate the influence of surgical and prosthetic variables, including basal seating guide design.",[29],"2026-01-18",{"date":246,"type":35},"2026-01-20",{"date":248,"type":35},"2024-01-01",{"date":250,"type":23},"2026-05-01",{"name":252,"class":42},"Menoufia University",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":17,"sex":51,"minAge":109,"maxAge":110,"enrollmentInfo":260,"targetDuration":4,"studyType":24,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":101},"100435779","ridge-augmentation-using-allograft-particles-hydrated-with-or-without-recombinant-human-platelet-derived-growth-factor-100435779","NCT04954664","Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor","Lateral Ridge Augmentation Using Allograft Bone Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor: A Clinical and Histological Randomized Controlled Trial","Inclusion Criteria:\n\n* English speaking\n* At least 18 years old\n* Must be a patient of the UAB Dental School\n* Able to read and understand informed consent document\n* Need for implants to replace missing tooth or teeth in at least one quadrant of the mouth.\n* Insufficient alveolar ridge width for endosseous implant placement defined as 5mm or less as determined by bone sounding and cone beam computed tomography (CBCT) scan.\n\nExclusion Criteria:\n\n* Non-English speaking\n* Less than 18 years old\n* Smokers\u002Ftobacco users (\\>10 cigarettes\u002Fday)\n* Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing\n* Patient is a poor compliance risk (i.e., poor oral hygiene, history of alcohol or drug abuse)\n* Vertical loss of bone at edentulous ridge.",{"count":261,"type":23},44,[26],"This study will compare two techniques to achieve increase in ridge dimensions as a preparation for dental implants using a resorbable barrier membrane and bone particulate allogenic graft hydrated with saline or a growth factor called Recombinant Human Platelet-Derived Growth Factor (rhPDGF).",[265,29],"Dental Implant",[267,268],"New bone","Dental implants","2025-12-19",{"date":271,"type":35},"2025-12-29",{"date":273,"type":35},"2021-08-11",{"date":275,"type":23},"2027-12",{"name":127,"class":42},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":17,"sex":51,"minAge":109,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":24,"phases":287,"briefSummary":288,"conditions":289,"keywords":292,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":307,"locationsCount":101},"100553729","lutein-zeaxathin-and-fish-oil-supplementation-100553729","NCT06489873","Lutein, Zeaxathin, and Fish Oil Supplementation","The Role of Lutein, Zeaxanthin, and Fish Oil on Cognitive Function and Bone Health in Healthy Adults","Inclusion Criteria:\n\n* \\\u003C.43 MPOD, a self-reported best-corrected vision of 20\u002F40 or better in each eye, a BMI range of 18.5-30, and meets the inclusion criteria on the preliminary participant questionnaire.\n\nExclusion Criteria:\n\n* allergic to lutein, zeaxanthin, or fish oil, taking supplements with \\>6 mg lutein and\u002For \\>2 mg zeaxanthin for more than two months before study starts, MPOD between \\>.43, self-reported condition of vertigo, diabetic retinopathy, retinitis pigmentosa, optic neuropathy, retinal vascular occlusions, strabismus, autoimmune disorders related to visual health, currently pregnant or trying to become pregnant, history of concussion, vegan (due to gelatin in the placebo), and\u002For taking neuroactive medications, such as Ritalin, Adderall, antidepressants, etc.","45 Years",{"count":286,"type":23},80,[26],"The goal of this clinical trial is to learn the impact of lutein, zeaxanthin, and fish oil (LZF) supplementation in healthy adults.\n\nThe main question it aims to answer is: Will supplementation with LZF improve macular pigment optical density (MPOD), cognitive performance and bone mass compared to controls after six months?\n\nSubjects with an MPOD \\\u003C.43 will significantly improve MPOD after 6-months of LZF supplementation.\n\nConsuming a LZFO supplement for 6-months will improve visual cognitive performance. Consuming a LZFO supplement for 6-months will improve bone density.\n\nParticipants will be asked to take either a LZF supplement or placebo daily for 6 months.",[290,291,29],"Cognitive Performance","Age-Related Macular Degeneration",[293,294,295,296,297,298,299,300,290],"Lutein","Zeaxanthin","Fish Oil","Supplement","Macular Pigment","Macular Pigment Optical Density","Cognition","Age-related Macular Degeneration","2025-09-24",{"date":303,"type":35},"2025-09-30",{"date":305,"type":35},"2024-02-07",{"date":250,"type":23},{"name":308,"class":42},"Texas A&M University",{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":239,"enrollmentInfo":316,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":101},"100608083","prospective-outcomes-of-guided-equator-overdentures-100608083","NCT07196943","Prospective Outcomes of Guided Equator Overdentures","Outcomes of Implant-Supported Equator Overdentures Following Fully Guided Static Implant Surgery: A Prospective Study","* Inclusion Criteria:\n\n  * Completely edentulous mandible requiring implant-supported overdenture rehabilitation\n  * Adequate bone volume to accommodate four implants in a quadrilateral configuration, confirmed by cone-beam computed tomography (CBCT)\n  * Age between 40 and 75 years\n  * Good general health with no systemic contraindications to implant surgery\n  * Willingness and ability to provide informed consent\n  * Commitment to attend all scheduled follow-up visits over the 3-year study period\n* Exclusion Criteria:\n\n  * Uncontrolled systemic diseases (e.g., diabetes mellitus, osteoporosis)\n  * History of radiotherapy in the head and neck region\n  * Untreated oral infections or severe periodontal disease\n  * Poor oral hygiene or inability to comply with maintenance protocols\n  * Heavy smoking (\\>10 cigarettes\u002Fday) or alcohol abuse\n  * Known allergy or intolerance to materials or medications used in the study",{"count":241,"type":23},"This prospective clinical study evaluated the 3-year performance of mandibular implant-supported overdentures (IODs) placed using a fully guided static computer-assisted implant surgery (CAIS) protocol. Primary outcomes included implant survival, peri-implant soft tissue health, and marginal bone loss. Findings provide evidence for the predictability of digital surgical workflows in removable prosthodontics.",[29],"2025-09-20",{"date":321,"type":35},"2025-09-29",{"date":323,"type":35},"2025-09-01",{"date":325,"type":23},"2028-12-01",{"name":252,"class":42},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":17,"sex":51,"minAge":334,"maxAge":239,"enrollmentInfo":335,"targetDuration":4,"studyType":24,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":342,"leadSponsor":343,"locationsCount":4},"100608028","crestal-bone-response-to-narrow-vs-regular-tie-base-in-subcrestal-implants-100608028","NCT07196228","Crestal Bone Response to Narrow vs. Regular Tie-Base in Subcrestal Implants","Evaluation of Crestal Bone Changes at Subcrestal Bone-level Implants With Narrow or Regular Tie-base: A Randomized Controlled Trial","\\*\\*Inclusion Criteria\n\nAdults ≥18 years old.\n\nSingle missing tooth in a posterior quadrant, bordered by adjacent natural teeth.\n\nAdequate bone volume to place implants 8.5-10 mm in length and 4 mm in diameter without the need for bone or soft tissue grafting.\n\nPresence of a natural tooth or an implant-supported fixed restoration as an antagonist.\n\nGood oral hygiene with a plaque index \\\u003C25%.\n\nWilling and able to comply with study procedures and follow-up schedule.\n\nProvided written informed consent.\n\n\\*\\*Exclusion Criteria\n\nSystemic conditions or medications affecting bone metabolism (e.g., bisphosphonates, corticosteroids).\n\nUntreated periodontitis, persistent oral infections, or poor oral hygiene.\n\nMetabolic bone diseases (e.g., osteoporosis, renal insufficiency, immunodeficiency, leukocyte dysfunction).\n\nHistory of head and neck radiotherapy.\n\nPhysical or mental disability preventing adequate oral hygiene or compliance.\n\nHeavy smoking (\\>10 cigarettes\u002Fday).\n\nAlcoholism or drug abuse.\n\nPregnancy or breastfeeding.\n\nBruxism or oral mucosal diseases.\n\nNeed for bone regeneration procedures before implant placement.\n\nInability or unwillingness to attend follow-up visits.","20 Years",{"count":241,"type":23},[26],"This 24-month randomized clinical trial evaluates peri-implant marginal bone changes at subcrestal implants restored with narrow versus regular tie-base abutments.\n\nThe study investigates whether narrow or regular tie-base abutments influence peri-implant crestal bone remodeling over 24 months.\n\nThis trial assesses the effect of abutment diameter (narrow vs. regular tie-base) on marginal bone stability at subcrestal implants after 24 months.\n\nWe aimed to determine if abutment diameter impacts peri-implant marginal bone levels by comparing narrow and regular tie-base abutments in a 24-month RCT.",[29],"2025-09-19",{"date":321,"type":35},{"date":303,"type":23},{"date":325,"type":23},{"name":252,"class":42},{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":17,"sex":51,"minAge":109,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":24,"phases":353,"briefSummary":354,"conditions":355,"keywords":356,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":364,"leadSponsor":366,"locationsCount":101},"100604945","prosthetic-modality-and-mbl-100604945","NCT07156110","Prosthetic Modality and MBL","The Effect of Prosthetic Modality on Bone Level Changes During One-Year Follow-Up","Inclusion criteria: 1. Male or female ≥18 years old. 2. One or more adjacent missing teeth in the posterior maxilla or mandible (positions 4-7). A natural tooth had to be present at the mesial end; however, free-end situations were allowed. 3. Adequate bone quality )D1-3) and availability for Lance Conical implant (MIS Implants, Israel) placement of diameters 3.75 mm or 4.2 mm, length 10-13 mm, 4. Patients are willing to participate and attend the planned follow-up visits.\n\nSystemic exclusion criteria: 1. Medical conditions requiring prolonged use of steroids and\u002For medications that can interfere with bone metabolism. 2. History of leukocyte dysfunction and deficiencies. 3. History of neoplastic disease requiring the use of radiation or chemotherapy. 4. History of renal failure. 5. Metabolic disorders such as osteoporosis. 6. History of uncontrolled endocrine disorders. 7. Physical handicaps that would interfere with the ability to perform adequate oral hygiene. 8. Use any investigational drug or device within 30 days immediately before implant surgery. 9. Alcoholism or any drug abuse. 10. History of immunodeficiency syndromes. 11. Smokers of 10 cigarettes per day, cigar equivalents, or tobacco chewers. 12. In the investigator's opinion, conditions or circumstances would prevent completion of study participation or interfere with the analysis of the study results, such as history of non-compliance or unreliability.\n\nLocal exclusion criteria\n\n1. Any bone augmentation performed on the implant site with a healing period of less than 3 months.\n2. Local inflammation (including untreated periodontitis).\n3. Mucosa disease such as erosive lichen planus\n4. History of local irradiation therapy.\n5. Presence of osseous lesions\n6. History of implant failure\n7. Postextraction sites with less than 6 weeks of healing\n8. Sever bruxism or cjenching habits\n9. Persistent intraoral infection.\n10. Bone type 4.\n\nExclusion criteria at surgery\n\n1. Lack of primary stability less than 35 Ncm.\n2. Need for augmentation procedures during implant surgery.\n3. Inability to place the implant according to the prosthetic requirements.",{"count":352,"type":23},60,[26],"The present study will test the effect of different prosthetic modalities on conical and internal hex connection implants, assessing the radiographic MBL changes after one year.\n\nConsecutive patients fulfilling inclusion\u002Fexclusion criteria will enter the study. Once the implant is inserted, patients will be divided into three groups according to the time if their inclusion in the study.\n\nStudy groups (20 patients per group):\n\n1. Group 1: Placing Lance Conical implant with a healing abutment. Three months later, after an impression, a screw-retained restoration will be seated using a Ti-Base abutment.\n2. Group 2: Placing Lance+ (Internal Hex connection) implant with a healing abutment. Three months later, after an impression, a screw-retained restoration will be seated using a Ti-Base abutment.\n3. Group 3: Placing Lance Conical implant together with Connect Abutment (tightened to 30 Ncm) with a Connect healing cap (\"one time one abutment\"). Screw retained restoration after 3 months.\n\nConsecutive inclusion of patients - 1st- group 1, 2nd - group 2, 3rd - group 3 and vice versa.\n\nPrimary outcome variable: bone level changes 12 months post-loading",[29],[357,358,359],"Marginal bone level changes","prosthetic modalities","soft tissue adaptation","2025-09-03",{"date":362,"type":35},"2025-09-04",{"date":323,"type":23},{"date":365,"type":23},"2026-12-31",{"name":367,"class":42},"Studio Odontoiatrico Associato Dr. P. Cicchese e L. Canullo",{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":51,"minAge":109,"maxAge":4,"enrollmentInfo":375,"targetDuration":377,"studyType":113,"phases":4,"briefSummary":378,"conditions":379,"keywords":381,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":392},"100371178","an-international-multicenter-prospective-registry-on-post-traumatic-long-bones-defects-100371178","NCT04112992","An International, Multicenter, Prospective Registry on Post-traumatic Long Bones Defects","An International, Multicenter, Prospective Registry to Investigate Treatment Options and Their Outcomes on Post-traumatic Long Bones Defects","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Skeletally mature\n* Post traumatic bone defect \\> 2 cm either\n\n  * initially after injury or\n  * after surgical debridement\n* Informed consent obtained, i.e.:\n\n  * Ability to understand the content of the patient information\u002FICF\n  * Willingness and ability to participate in the clinical investigation according to the registry plan\n  * Signed and dated EC\u002FIRB approved written informed consent OR\n  * Written consent provided according to the IRB\u002FEC defined and approved procedures for patients who are not able to provide independent written informed consent\n\nExclusion Criteria:\n\n* Any oblique defect that has less than 8cm expansion when adding the defect size of all four cortices\n* Any not medically managed severe systemic disease\n* Pregnancy\n* Prisoners\n* Participation in any other medical device or medicinal product registry within the previous 3 months that could influence the results of the present registry",{"count":376,"type":23},600,"1 Year","Long bone defect (LBD) is defined as a focalized loss of bone tissue in any long bone of the upper or lower extremity. Long bone defects are a complex problem, that may arise as a complication of many different pathologies, such as trauma, tumors or infection. Whereas post-traumatic defects are the largest group.\n\nReports estimate that there are almost 4 million bone grafting procedures worldwide per year. However, limb reconstruction in the context of a bony defect is challenging and up to date there is little evidence and treatment recommendations.\n\nIn a multi-national approach, the aim of this project is to set up an international, multicenter registry to gather information and details on prevalence or incidence, current treatments, complications and outcome.",[380,29],"Limb Fracture",[382],"long bone defect","2025-08-28",{"date":385,"type":35},"2025-08-29",{"date":387,"type":35},"2024-07-03",{"date":389,"type":23},"2029-03-30",{"name":391,"class":42},"AO Innovation Translation Center",21,{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":239,"enrollmentInfo":400,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":407,"leadSponsor":409,"locationsCount":101},"100600158","mandibular-overdentures-retained-by-four-locator-attachments-versus-four-implant-bar-attachments-100600158","NCT07093853","Mandibular Overdentures Retained by Four Locator Attachments Versus Four-Implant Bar Attachments","Residual Ridge Changes in Mandibular Overdentures Retained by Four Locator Attachments Versus Four-Implant Bar Attachments: A 10-Year Retrospective Study","Inclusion Criteria:\n\n* Completely edentulous mandible and maxilla for at least 12 months.\n* Four interforaminal dental implants placed in the lateral incisor and first premolar regions.\n* Opposing maxillary complete denture constructed using a muco-compressive impression technique, with maximum denture base extension and lingualized occlusion.\n* Mandibular bone height between 15-25 mm at the symphysis region as measured on panoramic radiograph.\n* Minimum 10-year follow-up with adequate radiographic documentation.\n\nExclusion Criteria:\n\n* Systemic diseases affecting bone metabolism.\n* Parafunctional habits (e.g., bruxism).\n* Smokers of more than 10 cigarettes\u002Fday or those with alcohol abuse.\n* Patients with implant failures, missing follow-up data, or implants placed outside the interforaminal region.",{"count":22,"type":23},"This 10-year retrospective study investigates residual ridge changes in edentulous patients treated with mandibular overdentures (ODs) retained by either four Locator attachments or a four-implant bar system. Although two-implant ODs are well established, four-implant configurations may offer enhanced stability and function. Locator and bar attachments are commonly used, but their long-term effects on bone resorption patterns-especially posterior mandibular and anterior maxillary resorption-remain unclear. By standardizing implant positions, this study aims to directly compare the two systems to help guide clinicians in selecting the most effective attachment type for long-term success.",[29],"2025-07-22",{"date":405,"type":35},"2025-07-30",{"date":248,"type":35},{"date":408,"type":23},"2025-10-01",{"name":252,"class":42},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":51,"minAge":417,"maxAge":20,"enrollmentInfo":418,"targetDuration":4,"studyType":24,"phases":420,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":101},"100381464","induced-membrane-properties-in-children-and-adults-100381464","NCT04246944","Induced Membrane Properties in Children and Adults","EMIH","Inclusion Criteria:\n\n* All patients treated at CHU Amiens-Picardie for bone critical sized defect treated using the induced membrane reconstruction technique.\n* patients from 9 months to 60 years old\n\nExclusion Criteria:\n\n* Patients managed by another reconstruction technique for critical sized defect\n* Patients under guardianship, curators or deprived of liberty.\n* Pregnant and nursing women.\n* Patients who refused to participate in the study and to sign informed consent.","9 Months",{"count":419,"type":23},50,[26],"Bone reconstruction in critical sized defect (CSD) remains a real challenge in orthopedic surgery in children and adults. The Masquelet technique is an innovative therapeutic technique, which offers a bone reconstruction in two steps, by the formation of an induced membrane (IM) around a polymethylmethacrylate (PMMA) spacer placed into the bone defect. After, PMMA removal, the cavity is filled with corticocancellous graft allowing bone healing. Up to date, all angiogenesis and osteogenic properties of IM remain unknown. The purpose of this study is to characterize angiogenesis and osteogenic properties of IM in children and adults.",[29,423],"Surgery",[425,426],"induced membrane","critical size defect","2025-06-05",{"date":429,"type":35},"2025-06-08",{"date":431,"type":35},"2019-05-23",{"date":433,"type":23},"2030-01",{"name":435,"class":42},"Centre Hospitalier Universitaire, Amiens",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":51,"minAge":109,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":24,"phases":444,"briefSummary":445,"conditions":446,"keywords":449,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":466},"100572683","study-on-safety-and-performance-of-advancore-bone-void-filler-100572683","NCT06736457","Study on Safety and Performance of AdvanCore Bone Void Filler","Inclusion Criteria:\n\n* Adult subjects ≥ 18 years old, male or female.\n* Subjects who are eligible for a bone grafting\u002Fbone void filler procedure.\n* Subjects with bone lesions beyond the limits of the bone's self-healing ability.\n* Subjects, and\u002For an authorized representative, who are willing and capable of providing informed consent, participating in all testing associated with this clinical investigation at an approved clinical investigational center.\n* Subjects with only one fracture susceptible to treatment with an AdvanCore implant.\n\nExclusion Criteria:\n\n* Subjects with any AdvanCore contraindication for implantation or use.\n* Subjects with hypersensitivity to any of the AdvanCore components.\n* Subjects with infections or soft\u002Fgranulation tissue in the area to place bone graft.\n* Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study.\n* Women who are breastfeeding or of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion).",{"count":443,"type":23},190,[26],"The objective of this study is to evaluate the safety and performance of AdvanCore implantable bone graft through a 12-month follow-up period in a prospective, parallel-group design, non-controlled, open label, multi-center and real-world setting study. This study is intended to satisfy post-market clinical follow-up requirements of CE Mark in Europe.",[447,86,29,448],"Bone Fractures","Bone Graft",[450,451,452,453,454,455],"Bone graft","Bone substitute","Bone regeneration","AdvanCore","Beta-Tricalcium Phosphate","Synthetic bone graft","2025-05-30",{"date":458,"type":35},"2025-05-31",{"date":460,"type":35},"2025-05-29",{"date":462,"type":23},"2026-10",{"name":464,"class":465},"Artur Salgado SA","INDUSTRY",4,{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":17,"sex":51,"minAge":109,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":24,"phases":477,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":74},"100588004","phase-4-osteogenic-action-of-a-medical-device-based-on-beta-tricalcium-phosphate-btcp-100588004","NCT06935747","Osteogenic Action of a Medical Device Based on Beta-tricalcium Phosphate (BTCP)","Clinical Study to Analyze the Osteogenic Action of a Beta-tricalcium Phosphate-based Product in Bone Regeneration After the Extraction of Impacted Mandibular Third Molars.","BTCP","Inclusion Criteria:\n\n* Patients must be of legal age, generally defined as 18 years or older, to be able to provide adequate informed consent and understand the risks and benefits of the procedure.\n* Informed Consent: Patients must be willing to provide written informed consent to participate in the study, indicating their understanding and acceptance of the associated procedures and risks.\n* Need for Extraction of Impacted Mandibular Third Molars: Patients must require the extraction of both impacted mandibular third molars to be eligible for the study.\n* Similar Complexity of Impacted Third Molars: The impacted mandibular third molars must present similar complexity for extraction on both sides of the jaw, to ensure a fair comparison between the study groups.\n* Absence of Medical Contraindications for Oral Surgical Procedures: Patients must not have significant medical contraindications that would prevent oral surgical procedures, such as clotting disorders, uncontrolled systemic diseases, or a history of severe infections.\n\nExclusion Criteria:\n\n* Severe Mental Disorders: Patients with severe mental disorders that may affect their ability to understand and follow study instructions may be excluded due to concerns about their capacity to provide valid informed consent and follow the study protocol.\n* Contraindications for Dental Extractions: Patients with specific contraindications for dental extraction, such as a history of osteonecrosis of the jaws or serious complications associated with previous dental procedures, may be excluded for safety reasons.\n* Patients under the age of 18 will not be eligible to participate in the study due to ethical and legal concerns related to obtaining informed consent and the ability to understand the risks and benefits of the study.\n\nWithdrawal from the Study:\n\n-If a patient experiences severe complications during the study, such as severe postoperative infections, severe allergic reactions, or any other adverse event that may jeopardize their health, they will be considered for withdrawal from the study to ensure their well-being. Additionally, if a patient decides to voluntarily withdraw from the study at any time, their decision will be respected, and appropriate medical care will be provided as needed.",{"count":476,"type":23},30,[55],"The general objective of this split-mouth study is to analyze the osteogenic action of BTCP during the bone regeneration process following the extraction of impacted mandibular third molars.",[29,480,481],"Regenerative Inflammation","Third Molars Extraction","2025-04-21",{"date":484,"type":35},"2025-04-24",{"date":486,"type":23},"2025-07",{"date":488,"type":23},"2026-07",{"name":490,"class":42},"Mario Pérez Sayáns",{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":51,"minAge":188,"maxAge":239,"enrollmentInfo":498,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":500,"conditions":501,"keywords":502,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":101},"100543913","biomechanical-effects-of-digitally-constructed-subperiosteal-implants-100543913","NCT06362057","Biomechanical Effects of Digitally Constructed Subperiosteal Implants","Biomechanical Effects of Digitally Constructed Subperiosteal Implants From Different Materials With Different Prosthetic Superstructures on Atrophied Maxilla: A Finite Element Analysis","Inclusion Criteria:\n\n* A 3D image of an edentulous maxilla bone derived from a computed tomography scan of an adult patient.\n* Maxilla with Cawood and Howell class 4 or 5 classification\n\nExclusion Criteria:\n\n* A 2D image of an edentulous maxilla bone\n* A non atrophied maxilla",{"count":499,"type":23},9,"Subperiosteal implants were first introduced in 1940 and then used worldwide for the treatment of edentulous maxilla or mandible with advanced bone atrophy.",[29],[503,504,505],"Polyetherketoneketone","Titanium","Polyethereetherketone","2025-03-25",{"date":508,"type":35},"2025-03-27",{"date":510,"type":35},"2024-04-04",{"date":512,"type":23},"2025-07-27",{"name":252,"class":42},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":51,"minAge":109,"maxAge":521,"enrollmentInfo":522,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":524,"conditions":525,"keywords":534,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":567},"100540952","cohort-study-on-plant-based-diets-coplant-study-100540952","NCT06323538","Cohort Study on Plant-based Diets (COPLANT Study)","COPLANT","Inclusion Criteria:\n\n* age between 18 and 69 years at recruitment (age-stratified recruitment in four age groups (18 to 29, 30 to 39, 40 to 49 and 50 to 69 years) which should be equally distributed across the four diets)\n* following their current diet for at least one year\n* health insured\n* are willing to have blood taken (adults)\n* are willing and able to complete questionnaires\n* only at Berlin, Jena, Giessen and Karlsruhe sites: pregnant and breastfeeding women were recruited (shortened examination programm)\n* only at the Regensburg, Heidelberg, Bonn and Vienna sites: are neither pregnant nor breastfeeding at the time of recruitment\n* only at Berlin and Karlsruhe sites: children of adult participants (shortened examination programm without collection of blood, urine, and stool)\n* are able to give informed consent to participate in the study\n* have given their consent to participate in the COPLANT study\n\nExclusion Criteria:\n\n* who can no longer be contacted\n* who withdraw their consent to participate in the study","69 Years",{"count":523,"type":23},6000,"The Cohort on Plant-based Diets (COPLANT) study is a multi-centre cohort study that starts baseline recruitment from 2024 to 2027 with approximately 6,000 participants in Germany and Austria. The COPLANT study focuses on vegan (no animal products), vegetarian (no meat and fish, but dairy products and eggs), pescetarian (no meat, but fish) and omnivorous (mixed diet including all possible animal products) diets. The aim of the COPLANT study is to gain new insights on health benefits and risks as well as social, ecological and economic effects of different plant-based diets in comparison to a mixed diet. In addition to a detailed dietary survey using an app adapted to the needs of this study, the baseline examination includes measurements of body composition, bone health, cardiovascular risk factors, diabetes risk, contaminants and lifestyle. For the basic laboratory program, fasting blood, 24-hour urine collection and a stool sample are taken from all study participants. Furthermore, specific aspects of dietary behavior, physical activity and other lifestyle factors are collected via questionnaires. Follow-up studies are planned at intervals of 5, 10 and 20 years after the baseline visit.",[526,527,528,29,529,530,531,532,533],"Dietary Exposure","Diabetes Mellitus, Type 2","Cardiovascular Diseases","Sustainability","Exposure","Obesity","Vitamin Deficiency","Mineral Deficiency",[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557],"vegan","vegetarian","pescetarian","omnivor","multicenter cohort","biomarker","vitamins","minerals","bone health","cardiovascular risk","body composition","inflammation","contaminants","diabetes type 2","thyroid gland health","microbiota","metabolomics","adults","children","pregnancy","breast feeding time","mental health","sustainability","2025-02-13",{"date":560,"type":35},"2025-02-14",{"date":562,"type":35},"2024-04-09",{"date":564,"type":23},"2047-03-31",{"name":566,"class":42},"German Federal Institute for Risk Assessment",8,{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":51,"minAge":109,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":576,"conditions":577,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":101},"100417291","bone-density-and-vascular-calcifications-evolution-after-renal-transplant-100417291","NCT04713774","Bone Density and Vascular Calcifications Evolution After Renal Transplant","Evolution of Bone Density, Bone Micro-architecture and Vascular Calcifications in Patients After Kidney Transplantation","Inclusion Criteria:\n\n* At least 18 years old\n* Recent kidney transplant patients (\\\u003C3 months)\n* Medical history available\n* Biological parameters of the past year available\n\nExclusion Criteria:\n\n* Treatment with bisphosphonate, RANKL inhibitor or SERM with bone action in the last 3 months before the transplant\n* Multiple organ transplant patients",{"count":419,"type":23},"The investigators project is based on:\n\n* Assessment of bone architecture by high resolution peripheral scanner (HRpQCT) and bone densitometry (DEXA);\n* The non-invasive detection of vascular calcifications (by abdominal CT scanner) and bone abnormalities associated with kidney transplantation, as well as the analysis of evolution over time;\n* Longitudinal evaluation of nephrological clinical parameters (glomerular filtration rate, number and type of rejections, immunosuppressive medications) as well as biological and urinary parameters of mineral metabolism (parathormone, sclerostin, bone alkaline phosphatase) depending on the type and severity of bone abnormalities;\n* The evaluation of these nephrological clinical parameters and of the biological parameters of mineral metabolism depending on the extent and evolution of vascular calcifications but also on bone morphology;\n* The study of possible relationships between bone mass and muscle mass (and functioning)",[578,29],"Kidney Transplant; Complications","2024-12-13",{"date":581,"type":35},"2024-12-18",{"date":583,"type":35},"2020-09-01",{"date":585,"type":23},"2026-12-13",{"name":587,"class":42},"University of Liege",{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":51,"minAge":334,"maxAge":20,"enrollmentInfo":594,"targetDuration":4,"studyType":24,"phases":595,"briefSummary":596,"conditions":597,"keywords":598,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":4},"100569228","radiographic-assessment-of-the-accuracy-of-3d-ridge-augmentation-in-anterior-mandible-using-computer-guided-autogenous-cortical-shell-technique-versus-free-hand-technique-100569228","NCT06691516","Radiographic Assessment Of The Accuracy Of 3D Ridge Augmentation In Anterior Mandible Using Computer Guided Autogenous Cortical Shell Technique Versus Free Hand Technique","Inclusion Criteria:\n\n* Age ranges from 20-60 years. No sex predilection.\n\nPatients free from any systemic conditions and bone metabolism diseases that might interfere with the surgical intervention, soft tissue or hard tissue healing.\n\nEdentulous anterior mandible with a horizontally deficient alveolar ridge that is less than 3mm in width and with a vertically defect at least 3mm in height.\n\nThe minimum number of missing teeth in the anterior mandible alveolar ridge is two adjacent teeth.\n\nExclusion Criteria:\n\n* Intra-bony lesions (e.g., cysts) or infections (e.g., abscess) that may retard the osteotomy healing.\n\nPrevious grafting procedures in the edentulous area",{"count":22,"type":23},[26],"\\* this study aims to evaluate accuracy of fixation of the bone shells by a calculated distance which is always a challenging step for inexperienced surgeons to fix a cortical shells at the ideal position in the conventional protocol.\n\nthe fixation guides used to make the shells precisely fixed at the proper position and angulation the problem is if it fixed with insufficient distance with proposed volume loss leads to totally insufficient volume gain for future implant placement\n\n* also to evaluate the efficacy of the CAD\u002FCAM surgical guide during chin harvesting (harvesting guide ) procedure in reducing the risk of anatomical structure damage (mental neve) and patient morbidity with more accuracy compared with the standard technique and preserve the roots of the lower anterior teeth or any fracture to the inferior border of the mandible also allow to harvest the bone shells from the suitable area with cancellous bone which prevent bad split of the bone shells this trial versus free hand conventional cortical shell bone technique both harvested from symphysis area (chin),\n* also to evaluate thickness of implanted bone shells , the thickness should be enough to preserve the graft(autograft 50% and xenograft 50%) between the buccal and lingual bone shells\n* also aims to evaluate the vertical and horizontal bone augmentation achieved at the anterior mandible using computer-guided cortical shell bone technique.",[29],[599],"cortical shell , bone loss , computer guided","2024-11-14",{"date":602,"type":35},"2024-11-15",{"date":604,"type":23},"2024-11-21",{"date":606,"type":23},"2026-03-01",{"name":608,"class":42},"Cairo University",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":4,"eligibilityCriteria":615,"healthyVolunteers":17,"sex":51,"minAge":616,"maxAge":239,"enrollmentInfo":617,"targetDuration":4,"studyType":24,"phases":618,"briefSummary":619,"conditions":620,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":101},"100567315","short-implant-versus-crestal-standard-length-implant-to-retain-class-1-removable-partial-denture-100567315","NCT06666595","Short Implant Versus Crestal Standard Length Implant to Retain Class 1 Removable Partial Denture.","Clinical Outcome of Subcrestal Short Implant Versus Crestal Standard Length Implant to Retain Kennedy Class 1 Removable Partial Denture: A Split-mouth Study","Inclusion Criteria\n\n* adult patients aged 50 years or older with class 1 RPD with missing mandibular molars at least and complaining from instability of the prosthesis were recruited.\n* Medical history revealed no contraindication to implant therapy.\n* Patients have an amount of bone nearly equal to 8 mm length above the inferior alveolar canal to receive a 6 mm short implant with 2 mm subcrestal to the bone level with sufficient bone width ≥ 8mm on one side and an amount of bone equal to or more than 8 mm to receive a standard-length implant of 7.5, 9, or 10.5 mm placed at crestal bone level with sufficient bone width ≥ 8mm on the contralateral side which was examined by CBCT.\n\nExclusion Criteria:\n\n* Presence of active infection or inflammation in the areas intended for implant placement; \\*systemic diseases such as diabetes.\n* Pregnant and lactating patients.\n* Habit of severe bruxism or clenching.\n* Treatment with therapeutic radiation to the head within the past 12 months.\n* Treatment with bisphosphonate within the past 12 months.\n* More than 10 cigarettes\u002Fday smoking habit.","50 Years",{"count":476,"type":23},[26],"Objective: To report the implant survival rates, clinical, and radiographic outcomes of subcrestal short implant versus crestal standard length implant supported removable partial denture (RPD).",[29,621],"Partial Edentulism Class 1","2024-10-29",{"date":624,"type":35},"2024-10-30",{"date":626,"type":35},"2021-01-04",{"date":628,"type":23},"2025-08-01",{"name":252,"class":42},{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":636,"eligibilityCriteria":637,"healthyVolunteers":12,"sex":51,"minAge":638,"maxAge":639,"enrollmentInfo":640,"targetDuration":4,"studyType":24,"phases":642,"briefSummary":644,"conditions":645,"keywords":647,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":74},"100509791","phase-2-bone-in-ckd-alkali-response-bicarb-pilot-trial-100509791","NCT05918029","Bone in CKD Alkali Response (BICARb Pilot Trial)","Bone in CKD Alkali Response Pilot Trial (BICARb)","BICARb","Inclusion Criteria (Pediatric Inclusion):\n\n* Children 5-17 years old\n* Estimated eGFR \\>30 and \\\u003C90 ml\u002Fmin\u002F1.73m2 by CKiD U25 equations\n* Females of child-bearing potential must have had a menstrual period in the last month\n* Levels of PTH and alkaline phosphatase within 2x normal range and phosphorus within the normal range for age (per local laboratory reference assay)\n* 25-hydroxy Vitamin D ≥ 20 ng\u002FmL\n* Females of child-bearing potential must be willing to use one form of effective contraception over the course of the study\n* Proficiency in English or Spanish\n* For participants \\\u003C 18 years, the participant and\u002For parent\u002Fguardian capable of providing informed consent and assent (assessed by the provider)\n\nInclusion Criteria (Adult Inclusion):\n\n* Adults ≥ 18 years old\n* Estimated eGFR \\>30 and \\\u003C90 ml\u002Fmin\u002F1.73m2 by the new CKD-Epi without race\n* Pre-menopausal women of childbearing age must have had a menstrual period in the last month\n* Levels of PTH and alkaline phosphatase within 2x normal range and phosphorus up to 5.0 mg\u002FdL (per local laboratory reference assay)\n* Levels of 25-hydroxy Vitamin D ≥ 20 ng\u002FmL\n* Women of childbearing potential must be willing to use one form of effective contraception over the course of the study\n* Proficiency in English or Spanish\n\nExclusion Criteria (Pediatric and Adult):\n\n* Baseline potassium ≥ 5.5 mEq\u002FL or prior history of hyperkalemia in the last 6 months (potassium \\> 5.5 mEq\u002FL) or currently taking a potassium lowering agent\n* Alkali therapy within the prior 12 months\n* Baseline ECG with abnormalities associated with increased risk of arrythmia, excluding left ventricular hypertrophy\n* Baseline serum bicarbonate levels \\\u003C 17 or ≥ 30 mEq\u002FL\n* Serum calcium \\\u003C 8.6 mg\u002FdL, adjusted for serum albumin\n* Significant comorbidity causing acid-base imbalance (e.g., active cancer requiring chemotherapy, chronic liver failure, moderate or severe chronic obstructive lung disease, New York Heart Association class 2 or greater congestive heart failure, obstructive sleep apnea requiring nightly continuous positive airway pressure, active glomerular disease requiring immunosuppressive therapy, intestinal malabsorption or celiac disease)\n* Plans to relocate out of the area in the next 3 months\n* Urine pH \\> 8 or history of nephrolithiasis\n* Lower extremity amputations or non-ambulatory\n* Metabolic bone disease not related to CKD (e.g., Paget's disease, primary hyperparathyroidism)\n* Endocrinopathy: untreated hyper or hypothyroidism, Cushing's syndrome\n* Medical diseases that can affect therapy (severe myocardial damage, acute dehydration, delayed gastric emptying, esophageal compression, or intestinal obstruction or stricture)\n* Use of bisphosphonates, denosumab, teriparatide, abaloparatide, romosozumab, raloxifene, estrogen or testosterone replacement therapy, or an unstable dose of glucocorticoids within the 12-months prior to enrollment\n* Previous bilateral wrist and tibia fractures\n* Solid or liquid organ transplant\n* On dialysis or with rapidly deteriorating kidney function or expectation for transplantation or initiation of dialysis in less than 3 months\n* Pregnancy or breastfeeding\n* Prisoners or institutionalized individuals\n* Unwillingness to provide informed consent","5 Years","100 Years",{"count":641,"type":23},103,[643,192],"PHASE2","The goal of this clinical trial is to test whether potassium citrate improves skeletal health in adults and children with chronic kidney disease. The main questions it aims to answer are:\n\n* To evaluate effects of potassium citrate treatment on bone quality and strength.\n* To evaluate mechanism(s) underlying the effects of potassium citrate on skeletal health.\n\nParticipants will be asked to:\n\n* provide blood, urine and answer questions about health and diet three times during an 8 months period\n* undergo advanced bone imaging with high resolution-peripheral quantitative CT scan twice during 8 months\n* take study pills for 4-6 weeks at the beginning of the study to ensure safety\n* take either potassium citrate or placebo for 6 months during the blinded portion of the study\n\nAs part of the study, there will be a run-in period followed by the placebo-controlled randomized clinical trial. Researchers will compare the bone imaging between the potassium citrate and the placebo groups at the end of the study.",[646,29],"Chronic Kidney Diseases",[648,649,650,651,652],"Chronic Kidney Disease","Bone strength","Fractures","Pediatrics","Metabolic acidosis","2024-10-11",{"date":655,"type":35},"2024-10-15",{"date":657,"type":35},"2024-08-15",{"date":659,"type":23},"2026-08",{"name":661,"class":42},"Albert Einstein College of Medicine"]